Kaleido Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Kaleido Biosciences generated cash of $0, which is more than the previous year. Cash used in financing activities reached the amount of $0 last year.
Cash Flow
| 2016 | -9.35M | -195K | 10.93M |
|---|---|---|---|
| 2017 | -22.49M | -1.40M | 49.73M |
| 2018 | -46.31M | -3.00M | 98.90M |
| 2019 | -75.79M | -3.58M | 74.64M |
| 2020 | -61.51M | -4.02M | 40.39M |
| 2021 | -77.09M | -691K | 70.03K |
| 2022 | 0 | 0 | 0 |
KLDO Cash Flow Statement (2016 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 38.47M | 48.38M | 73.52M | 78.26M | 28.67M | 2.84M | 1.45M |
Operating activities | |||||||
Net income | 0 | -90.28M | -81.62M | -86.33M | -61.74M | -27.55M | -9.68M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 0 | 2.35M | 1.82M | 1.31M | 792K | 316K | 99K |
Stock-based compensation expense | 0 | 10.34M | 12.68M | 10.06M | 0 | 590K | 58K |
| Deferred income tax benefit | 0 | 10.34M | 12.68M | 10.06M | 0 | 590K | 58K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 281K | 3.30M | -684K | 1.83M | 13K | 298K |
Cash generated by operating activities | 0 | -77.09M | -61.51M | -75.79M | -46.31M | -22.49M | -9.35M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -1.12M | -4.02M | -3.58M | -3.00M | -1.40M | -195K |
Acquisitions Net | 0 | 438K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | -691K | -4.02M | -3.58M | -3.00M | -1.40M | -195K |
Financing activities | |||||||
Common Stock Issued | 0 | 70.39M | 37.75M | 67.76M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -339 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -68K | 7.40M | -105K | 9.87M | -46K |
Cash used in financing activities | 0 | 70.03K | 40.39M | 74.64M | 98.90M | 49.73M | 10.93M |
Net Change In Cash | 0 | -7.74M | -25.14M | -4.74M | 49.58M | 25.83M | 1.38M |
Cash at end of period | 38.47M | 40.63M | 48.38M | 73.52M | 78.26M | 28.67M | 2.84M |
| Data source | Data source | Data source |